Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.53 |
| ▸ | RXRB | P28702 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501260 | 0.83 | CA2 (0.50) | RXRARXRBPOLBALDH1A1RXRG | |
| SCHEMBL23927618 | 0.80 | FFAR1 (0.51) | ALDH1A1 | |
| SCHEMBL3272550 | 0.80 | MLYCD (0.44) | RXRARXRBNPC1POLBRAB9A | |
| SCHEMBL506422 | 0.80 | RXRA (0.47) | RXRARXRBALDH1A1RXRGRARB | |
| SCHEMBL9889127 | 0.80 | TAAR1 (0.45) | ALDH1A1KMT2APARP1 | |
| SCHEMBL9902946 | 0.79 | RXRA (0.49) | RXRARXRBNPC1POLBRAB9A | |
| SCHEMBL18824993 | 0.78 | PARP1 (0.41) | PARP1 | |
| SCHEMBL31146913 | 0.78 | ALDH1A1 (0.51) | RXRARXRBSMN1; SMN2ALDH1A1NR4A1 | |
| SCHEMBL1315107 | 0.77 | TSHR (0.46) | ALDH1A1PARP1 | |
| SCHEMBL3271553 | 0.77 | CYP19A1 (0.47) | NPC1RAB9ASMN1; SMN2KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683911-A1 | NOVEL TAG FOR LIQUID-PHASE PEPTIDE SYNTHESIS | CordenPharma International GmbH (DE) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024194387-A1 | NOVEL TAG FOR LIQUID-PHASE PEPTIDE SYNTHESIS | CORDENPHARMA INTERNATIONAL GMBH (DE) | 2024-09-26 | — | — | WO | disclosed |
| US-7825254-B2 | Heteroaromatic quinoline compounds | PFIZER INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1979343-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | RXRA 3862/4885RXRB 3991/4885NPC1 2427/4885 |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | RXRA 3899/4885RXRB 3937/4885NPC1 1991/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | RXRA 3862/4885RXRB 3991/4885NPC1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.